© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
isoform-selective mutant PI3K_ degrader
oral <9 mg QD, Ph. III in HR+/HER2- BC
from cellular characterization of PI3Ki and opt.
bioRxiv, May 13, 2021
Genentech, South San Francisco, CA
The Genentech PI3Kα isoform-selective kinase inhibitor and mutant PI3Kα degrader GDC-0077 (inavolisib) selectively depletes the oncogenic mutant p110α catalytic subunit of PI3Kα in cancer cells with active receptor tyrosine kinase (RTK)…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.